MX2012007676A - Nueva formulacion de anticuerpo. - Google Patents
Nueva formulacion de anticuerpo.Info
- Publication number
- MX2012007676A MX2012007676A MX2012007676A MX2012007676A MX2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody formulation
- formulation
- egfr
- preparation
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Abstract
La presente invención se refiere a una formulación farmacéutica de un anticuerpo contra el receptor del factor de crecimiento epidérmico (EGFR), a un procedimiento para la preparación de la misma y a usos de la formulación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09180840 | 2009-12-29 | ||
PCT/EP2010/070625 WO2011080209A2 (en) | 2009-12-29 | 2010-12-23 | Novel antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007676A true MX2012007676A (es) | 2012-08-03 |
Family
ID=43618150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007676A MX2012007676A (es) | 2009-12-29 | 2010-12-23 | Nueva formulacion de anticuerpo. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20110158987A1 (es) |
EP (1) | EP2519262A2 (es) |
JP (1) | JP2013515754A (es) |
KR (1) | KR20120110175A (es) |
CN (1) | CN102686241A (es) |
AR (1) | AR079746A1 (es) |
AU (1) | AU2010338305A1 (es) |
BR (1) | BR112012013148A2 (es) |
CA (1) | CA2783715A1 (es) |
IL (1) | IL219592A0 (es) |
MX (1) | MX2012007676A (es) |
RU (1) | RU2012131099A (es) |
SG (1) | SG182304A1 (es) |
TW (1) | TW201200152A (es) |
WO (1) | WO2011080209A2 (es) |
ZA (1) | ZA201204266B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11857625B2 (en) | 2017-11-23 | 2024-01-02 | UCB Biopharma SRL | Pharmaceutical compositions |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103841963B (zh) * | 2011-08-12 | 2018-04-24 | 梅里亚股份有限公司 | 用于生物产品特别是疫苗的真空辅助保存 |
EP2879712B1 (en) | 2012-07-31 | 2018-04-25 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
CA2906101A1 (en) * | 2013-03-15 | 2014-09-18 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
WO2015134406A1 (en) * | 2014-03-03 | 2015-09-11 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
BR112016025126B1 (pt) * | 2014-05-07 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma |
CN105651848A (zh) * | 2014-11-13 | 2016-06-08 | 浙江海正药业股份有限公司 | 一种含有保护剂的毛细管凝胶电泳检测试剂盒 |
KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
EA037532B1 (ru) * | 2015-05-07 | 2021-04-08 | Новиммун Са | Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров |
US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
BR112018005349A2 (pt) * | 2015-09-28 | 2018-10-09 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
ES2823279T3 (es) * | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab |
CN109311986A (zh) * | 2016-03-25 | 2019-02-05 | 威特拉公司 | 登革热病毒抗体分子的制剂 |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
IT201600077232A1 (it) * | 2016-07-22 | 2018-01-22 | Bio Optica Milano S P A | Una preparazione liquida acquosa per la conservazione di un campione istologico |
CN109843920B (zh) * | 2016-08-29 | 2023-01-13 | 迪赞纳生命科学公开有限公司 | 抗cd3抗体制剂 |
CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
BR112019005328A2 (pt) * | 2016-09-27 | 2019-06-18 | Fresenius Kabi Deutschland Gmbh | composição farmacêutica líquida |
CN107987161B (zh) * | 2016-10-26 | 2021-04-16 | 泰州迈博太科药业有限公司 | 一种抗egfr单克隆抗体制剂 |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
TW201902462A (zh) * | 2017-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 用於免疫促效劑之新穎投與途徑 |
CN110869050A (zh) * | 2017-07-28 | 2020-03-06 | 豪夫迈·罗氏有限公司 | 双特异性抗体配制剂 |
KR102208378B1 (ko) * | 2017-08-17 | 2021-01-28 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
MA56102A (fr) * | 2019-06-07 | 2022-04-13 | Argenx Bvba | Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée |
CU20190104A7 (es) * | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业(上海)股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
WO2022166918A1 (zh) * | 2021-02-05 | 2022-08-11 | 百奥泰生物制药股份有限公司 | 一种抗il-5抗体制剂及其制备方法和应用 |
TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
WO2023246790A1 (zh) * | 2022-06-21 | 2023-12-28 | 广东菲鹏制药股份有限公司 | 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
NZ541503A (en) | 2003-01-22 | 2008-09-26 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
AR052469A1 (es) * | 2005-01-28 | 2007-03-21 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido |
EP2402374A1 (en) * | 2005-02-07 | 2012-01-04 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
CN103172737A (zh) * | 2005-06-30 | 2013-06-26 | Abbvie公司 | Il-12/p40结合蛋白 |
PL2960253T3 (pl) * | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
US7390786B2 (en) * | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
KR20080104160A (ko) * | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
US20100158925A1 (en) * | 2006-06-14 | 2010-06-24 | Meera Agarkhed | Lyophilized formulations of anti-egfr antibodies |
AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
CA2671968A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
CA2693611A1 (en) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
MX2010006395A (es) * | 2007-12-21 | 2010-07-01 | Hoffmann La Roche | Formulacion de anticuerpos. |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
-
2010
- 2010-12-23 JP JP2012546422A patent/JP2013515754A/ja active Pending
- 2010-12-23 MX MX2012007676A patent/MX2012007676A/es not_active Application Discontinuation
- 2010-12-23 EP EP10795400A patent/EP2519262A2/en not_active Withdrawn
- 2010-12-23 CA CA2783715A patent/CA2783715A1/en not_active Abandoned
- 2010-12-23 WO PCT/EP2010/070625 patent/WO2011080209A2/en active Application Filing
- 2010-12-23 RU RU2012131099/15A patent/RU2012131099A/ru unknown
- 2010-12-23 BR BR112012013148A patent/BR112012013148A2/pt not_active IP Right Cessation
- 2010-12-23 US US12/977,509 patent/US20110158987A1/en not_active Abandoned
- 2010-12-23 SG SG2012048591A patent/SG182304A1/en unknown
- 2010-12-23 AU AU2010338305A patent/AU2010338305A1/en not_active Abandoned
- 2010-12-23 KR KR1020127019717A patent/KR20120110175A/ko not_active Application Discontinuation
- 2010-12-23 CN CN201080059591XA patent/CN102686241A/zh active Pending
- 2010-12-27 AR ARP100104954A patent/AR079746A1/es unknown
- 2010-12-27 TW TW099146170A patent/TW201200152A/zh unknown
-
2012
- 2012-05-03 IL IL219592A patent/IL219592A0/en unknown
- 2012-06-11 ZA ZA2012/04266A patent/ZA201204266B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11857625B2 (en) | 2017-11-23 | 2024-01-02 | UCB Biopharma SRL | Pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
ZA201204266B (en) | 2014-11-26 |
WO2011080209A2 (en) | 2011-07-07 |
IL219592A0 (en) | 2012-06-28 |
KR20120110175A (ko) | 2012-10-09 |
AR079746A1 (es) | 2012-02-15 |
JP2013515754A (ja) | 2013-05-09 |
CA2783715A1 (en) | 2011-07-07 |
RU2012131099A (ru) | 2014-02-10 |
BR112012013148A2 (pt) | 2017-03-21 |
US20110158987A1 (en) | 2011-06-30 |
SG182304A1 (en) | 2012-08-30 |
AU2010338305A1 (en) | 2012-05-24 |
CN102686241A (zh) | 2012-09-19 |
TW201200152A (en) | 2012-01-01 |
WO2011080209A3 (en) | 2012-03-15 |
EP2519262A2 (en) | 2012-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007676A (es) | Nueva formulacion de anticuerpo. | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MY162825A (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
AU2009301431A8 (en) | Bispecific anti-VEGF/anti-ANG-2 antibodies | |
MX2012007340A (es) | Anticuerpos anti/her3 y usos de los mismos. | |
MY171841A (en) | Antibody formulation | |
PH12014502641B1 (en) | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof | |
WO2011130615A3 (en) | Preparation of lacosamide | |
IL222657A (en) | Epidermal Growth Factor Antibody Antibody Preparation (egfr) | |
HK1197071A1 (en) | Antibodies against epidermal growth factor receptor (egfr) and uses thereof (egfr) | |
WO2011161226A3 (en) | Novel antibody formulation | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
WO2010031720A3 (en) | Novel antibody formulation | |
TN2011000673A1 (en) | Bace inhibitors | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
WO2010070658A3 (en) | Improved process for the preparation of endothelin receptor antagonists | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
EP2615060A4 (en) | SILICON NITRIDE POWDER FOR A SILICONUMIDRIDE FLUORESCENCE MATERIAL, SR3AL3SI13O2N21 FLUORESCENCE MATERIAL AND BETA SIALON FLUORESCENCE MATERIAL MANUFACTURED THEREFROM, AND METHOD FOR PRODUCING THEREOF | |
GB201303865D0 (en) | Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein | |
IN2013MN00733A (es) | ||
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
MX349563B (es) | Formulacion farmaceutica de fenofibrato nanonizado. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |